Australian Research Peptide Rules Explained
A plain-language look at the regulatory context for research-use peptides in Australia and what labs should verify when sourcing compounds.
Read articleGLOW brings three research peptides together. A careful look at what each component is studied for, and why blend evidence is not the same as single-compound evidence.

What is in the GLOW peptide blend? Understand its three named components, the research behind each and why component evidence is not evidence for the mixture.
Check current availability and choose options on the product page. Research Use Only.
’s GLOW listing names three components: GHK-Cu, BPC-157 and TB-500, with a stated total amount of 70mg. A total amount does not tell you the amount of each component. Do not assume a ratio from a similarly named product elsewhere; check the current specification and available batch documentation.
The important evidence distinction is simple: a study of one component is not a study of the combined GLOW formulation. The three original papers discussed below did not test this mixture. They help explain component-level research questions and identity checks, not establish a benefit for GLOW. Research Use Only, for in vitro laboratory research and not for human or animal consumption.
GHK is a three-amino-acid peptide that binds copper. A 1988 paper by Maquart and colleagues examined GHK-Cu in fibroblast cultures and reported changes in collagen synthesis. Fibroblasts are cells involved in producing components of the extracellular matrix, the material surrounding cells. [ 1 ]
This is a cell-culture observation about a particular copper-peptide complex. It is not evidence that a three-component vial produces the same result, or that a visible appearance predicts biological activity. The GHK-Cu research overview places this component in its wider literature context.
In a 2014 study, Chang and colleagues examined BPC-157 in fibroblasts isolated from rat Achilles tendon. They reported increased growth-hormone receptor expression, measured at both RNA and protein levels, and examined downstream responses when growth hormone was added. [ 2 ]
This result concerns receptor expression and responses in a defined cell model. It does not mean BPC-157 is growth hormone, nor does it establish a result in people or in a GLOW mixture. For separate discussion of the two named components, see BPC-157 and TB-500 research distinctions .
A 2012 analytical paper identified an acetylated fragment corresponding to residues 17–23 of thymosin beta-4 in a product labelled TB-500. The authors used chromatography and mass spectrometry and synthesised the fragment as part of their characterisation work. [ 3 ]
That finding describes the tested product, not every product carrying the TB-500 label. It is a reason to verify sequence, molecular form and analytical identity rather than automatically treating a short fragment and full-length thymosin beta-4 as interchangeable. This article does not assign the fragment identified in that paper to ’s GLOW material.
No conclusion about synergy follows from these component papers. Synergy would require evidence that a combination behaves differently from what an appropriate comparison predicts. Simply citing three separate papers does not provide that comparison. The mixture, its component amounts, controls and endpoints would need to be part of the actual study.
For the same reason, findings from unrelated cell types cannot be added together into a single promised outcome. A blend name is a product identifier, not an experimental result. Where the exact formulation has not been tested in a cited experiment, describe that gap explicitly.
Do not infer that a single reported percentage establishes all three component amounts. Likewise, a report for one standalone component does not authenticate a mixed vial. Review the identity versus purity guide and COA reading guide before deciding what a document supports.
Start with the exact composition, then read the experimental evidence for that composition. Keep component studies clearly labelled as component studies. If an individual amount or analytical result is not supplied, record it as unconfirmed rather than filling the gap with an assumption.
The GLOW 70mg product page is the reference for the current listing and availability. This article makes no claim that GLOW has demonstrated human benefits, that its components are interchangeable, or that the cited research establishes the mixture’s stability. It provides no personal-use or administration instructions. Research Use Only.
Links lead to the original paper, DOI record, or open-access full text where available.
This compound is supplied for in vitro laboratory and educational research only. It is not listed on the Australian Register of Therapeutic Goods (ARTG) and is not a therapeutic good under the Therapeutic Goods Act 1989 (Cth). Not for human or animal consumption, therapeutic use, or diagnostic procedures. By purchasing, you confirm you are a qualified researcher or acting on behalf of a licensed research facility, and you assume full responsibility for the safe handling, storage, and lawful use of this compound.
A plain-language look at the regulatory context for research-use peptides in Australia and what labs should verify when sourcing compounds.
Read article
An overview of SS-31, its relationship with cardiolipin in mitochondrial membranes, and how laboratory findings differ from clinical claims.
Read article
The history of DSIP in sleep research, the small human studies that exist, and the limits of the current evidence base.
Read articleA comparison of three compounds frequently studied in tissue models, how their research backgrounds differ, and why they are often examined together.
Read articleTell us what you need. An email address is required so we can reply.